METROPOLIS · Healthcare · Diagnostics & Research
Composite scorecard: 40/100 — Quality 63 · Valuation 48 · Growth 24 · Momentum 0
| Share price | ₹573.75 |
| Market cap | ₹9,868 Cr |
| P/E ratio | 58.8 |
| P/B ratio | 6.9 |
| ROE | 13.9% |
| ROCE | 13.3% |
| Dividend yield | 0.21% |
| Book value | ₹276.61 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,646 Cr | ₹191 Cr | 24.0% |
| 2025 | ₹1,331 Cr | ₹146 Cr | 23.0% |
| 2024 | ₹1,208 Cr | ₹128 Cr | 24.0% |
| 2023 | ₹1,148 Cr | ₹143 Cr | 26.0% |
| 2022 | ₹1,228 Cr | ₹215 Cr | 28.0% |
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gy